| First Author | Azhar S | Year | 2019 |
| Journal | Mol Cell Endocrinol | Volume | 480 |
| Pages | 1-11 | PubMed ID | 30290217 |
| Mgi Jnum | J:273302 | Mgi Id | MGI:6286626 |
| Doi | 10.1016/j.mce.2018.09.011 | Citation | Azhar S, et al. (2019) Novel ABCA1 peptide agonists with antidiabetic action. Mol Cell Endocrinol 480:1-11 |
| abstractText | Previously, apoE-derived ABCA1 agonist peptides have been shown to possess anti-atherosclerotic and possibly antidiabetic properties. Here we assessed the in vitro and in vivo actions of a second generation of ABCA1 peptide agonists, CS6253 and T6991-2, on glucose homeostasis. The results show that these two peptides improve glucose tolerance in a prediabetic diet-induced obesity mouse model by enhancing insulin secretion. It was further demonstrated that T6991-2 also improved glucose tolerance in leptin-deficient (ob/ob) mice. CS6253 increased insulin secretion both under basal conditions and in response to high glucose stimulation in pancreatic INS-1 beta-cells rendered leptin receptor deficient with specific siRNA. Additional in vitro cell studies suggest that the CS6253 agonist attenuates hepatic gluconeogenesis and glucose transport. It also potentiates insulin-stimulated glucose uptake and utilization. These observed anti-diabetic actions suggest additional benefits of the CS6253 and T6991-2 ABCA1 peptide agonists for cardiovascular disease beyond their direct anti-atherosclerosis properties previously described. |
